The Appropriateness of Invasive Ventilation in COVID-19 Positive Cancer Patients: Proposal of a New Prognostic Score.


Journal

Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722

Informations de publication

Date de publication:
19 03 2021
Historique:
received: 06 02 2021
revised: 03 03 2021
accepted: 17 03 2021
entrez: 3 4 2021
pubmed: 4 4 2021
medline: 20 4 2021
Statut: epublish

Résumé

Over the last months, as oncology specialists, we have frequently been contacted for estimating prognosis for cancer patients affected by COVID-19 infection. Until now, there have been no clear markers to guide decision making regarding the appropriateness of invasive ventilation in cancer patients affected by COVID-19 infection. We developed a practical tool encompassing a prognostic score, "The Milano Policlinico ONCOVID-ICU score." The score is composed of three groups of variables: patient's characteristics such as sex, age, BMI, and comorbidities; oncological variables (treatment intent, life expectancy, on or off-treatment status); and clinical parameters in association with laboratory values (the Sequential Organ Failure Assessment (SOFA) score and D-dimer). The SOFA score includes six different clinical parameters and during the first few days of ICU admissions has an important prognostic role. The oncological history should never represent, per se, a contraindication to intensive care and must be considered together with other variables, such as laboratory values, clinical parameters, and patient characteristics, in order to make the hardest but best possible choice. To our knowledge, "The Milano Policlinico ONCOVID-ICU score" is the first prognostic score proposed in this setting of patients and requires further validation. This tool may be useful to assess the prognosis of cancer patients in critical conditions.

Identifiants

pubmed: 33808623
pii: v13030508
doi: 10.3390/v13030508
pmc: PMC8003474
pii:
doi:

Substances chimiques

Fibrin Fibrinogen Degradation Products 0
fibrin fragment D 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
ID : Italian fiscal contribution "5 x 1000" 2016

Références

Lancet Oncol. 2018 Jun;19(6):e305-e316
pubmed: 29893262
Clin Microbiol Infect. 2020 Jun;26(6):767-772
pubmed: 32304745
ESMO Open. 2016 Sep 13;1(5):e000018
pubmed: 27843637
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
J Crit Care. 2019 Apr;50:87-91
pubmed: 30502688
Crit Care. 2009;13(1):R15
pubmed: 19200368
Cancer Discov. 2020 Jun;10(6):OF1
pubmed: 32312714
Lancet Respir Med. 2020 May;8(5):506-517
pubmed: 32272080
Crit Care Med. 2007 Mar;35(3):808-14
pubmed: 17235261
Cancer Discov. 2021 Feb 26;:
pubmed: 33637485
JAMA. 2001 Oct 10;286(14):1754-8
pubmed: 11594901
Lancet Oncol. 2020 Mar;21(3):335-337
pubmed: 32066541
Anesthesiology. 2020 Jun;132(6):1317-1332
pubmed: 32195705

Auteurs

Michele Ghidini (M)

Medical Oncology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy.

Alice Indini (A)

Medical Oncology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy.

Erika Rijavec (E)

Medical Oncology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy.

Claudia Bareggi (C)

Medical Oncology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy.

Monica Cattaneo (M)

Medical Oncology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy.

Gianluca Tomasello (G)

Medical Oncology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy.

Barbara Galassi (B)

Medical Oncology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy.

Donatella Gambini (D)

Medical Oncology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy.

Francesco Grossi (F)

Medical Oncology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH